VivoSeq
Cardiovascular

Anterior Ischemic Optic Neuropathy

14

Pipeline Programs↗

1

Active Trials↗

9

Companies Involved↗

Anterior Ischemic Optic Neuropathy is an emerging landscape with 14 programs across 9 companies. The most active players are Roche, Regenera Pharma Ltd, Quark Pharmaceuticals. 7 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

6/100

Mech. Concentration

38/100

Completion Rate

57/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 1R

Regenera Pharma Ltd

1 program

Phase 2Q

Quark Pharmaceuticals

1 program

Phase 3Pfizer logo

Pfizer

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

ApprovedV

Viatris Specialty LLC

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

79%

Small molecule

15 of 19 classified programs — the dominant modality here.

21%ALL OTHERSMonoclonal antibody316%Protein / enzyme15%

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 100% of 19 pipeline programs.

Analysis

Trial Status

11

clinical trials

Completed4 · 36%
Unknown status3 · 27%
Terminated3 · 27%
Recruiting1 · 9%

Clinical Trials

Trial Activity

11 trials

Randomized, Multicenter, Vehicle-Controlled, Double-Masked Phase 3 Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Recruiting·—·Phase 3·NCT07453888·272 enrolled
Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
Completed·—·Phase 4·NCT03046693·38 enrolled
Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy
Completed·SShahid Beheshti University of Medical Sciences·Phase 4·NCT00432393
A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Completed·NNeuro-Ophthalmologic Associates, PC·Phase 4·NCT01975324·20 enrolled
Platelet-Rich Plasma for Acute Nonarteritic Anterior Ischemic Optic Neuropathy: A Prospective Randomized Controlled Study
Completed·UUludag University·N/A·NCT07330713·31 enrolled
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
Terminated·Bayer logoBayer·Phase 4·NCT00867815·10 enrolled
Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Terminated·RRegenera Pharma Ltd·Phase 2·NCT03547206·165 enrolled
Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Terminated·QQuark Pharmaceuticals·Phase 2/3·NCT02341560·732 enrolled
Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy
Unknown status·MMount Sinai Hospital, Canada·Phase 2·NCT00813059·10 enrolled
Effect of EECP on Anterior Ischemic Optic Neuropathy
Unknown status·FFirst Affiliated Hospital, Sun Yat-Sen University·N/A·NCT01768260·40 enrolled
Outcomes of Steroid and Oxygen Therapy Versus Placebo Therapy in Non-arteritic Anterior Ischemic Optic Neuropathy
Unknown status·SShahid Beheshti University of Medical Sciences·Phase 3·NCT02439866·90 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)